Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. (original) (raw)

• Journal List
• Proc Natl Acad Sci U S A
• v.81(17); 1984 Sep
• PMC391747

Proc Natl Acad Sci U S A. 1984 Sep; 81(17): 5566–5570.

Abstract

The beta-very low density lipoproteins (beta-VLDL) that accumulate in type III hyperlipoproteinemic subjects can be divided into two fractions (fraction I and fraction II), which differ in size, lipid composition, and the type of apolipoprotein B (apo-B) present in the particles. The apo-B48-containing particles (fraction I) are of intestinal origin, while apo-B100-containing particles (fraction II) are derived from the liver. Both fractions contain a defective form of apo-E referred to as apo-E2. Intravenous infusion of heparin into two subjects with type III hyperlipoproteinemia resulted in the complete removal of fraction II particles from density less than 1.006 g/ml, while fraction I particles remained at this density. In vitro studies confirmed that fraction I particles did not change density when subjected to hydrolysis with lipoprotein lipase, while fraction II particles shifted to the intermediate density lipoprotein range (approximately equal to 1.02 g/ml). When the beta-VLDL were hydrolyzed by lipoprotein lipase in the presence of density greater than 1.21 g/ml lipoprotein-deficient plasma, the addition of normal apo-E (apo-E3), but not apo-E2, resulted in a shift of fraction II particles to the low density lipoprotein (LDL) range (approximately equal to 1.05 g/ml). Fraction I particles did not undergo a shift to this higher density, supporting previous observations that apo-B48-containing particles are not converted to LDL. The demonstration that apo-B100-containing particles in type III hyperlipoproteinemic subjects could be converted to particles with the density of LDL suggests that apo-E plays a role in the normal conversion of VLDL to LDL. The mutant form of apo-E (apo-E2) found in the beta-VLDL from type III hyperlipoproteinemic subjects appears to impede this conversion, whereas the addition of normal apo-E (apo-E3) allows the processing to occur.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

• Havel RJ. Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis. Med Clin North Am. 1982 Mar;66(2):441–454. [PubMed] [Google Scholar]
• Mahley RW, Angelin B. Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia. Adv Intern Med. 1984;29:385–411. [PubMed] [Google Scholar]
• Fainaru M, Mahley RW, Hamilton RL, Innerarity TL. Structural and metabolic heterogeneity of beta-very low density lipoproteins from cholesterol-fed dogs and from humans with type III hyperlipoproteinemia. J Lipid Res. 1982 Jul;23(5):702–714. [PubMed] [Google Scholar]
• Kane JP, Chen GC, Hamilton RL, Hardman DA, Malloy MJ, Havel RJ. Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinemia. Arteriosclerosis. 1983 Jan-Feb;3(1):47–56. [PubMed] [Google Scholar]
• Kane JP, Hardman DA, Paulus HE. Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. Proc Natl Acad Sci U S A. 1980 May;77(5):2465–2469. [PMC free article] [PubMed] [Google Scholar]
• Mahley RW. Apolipoprotein E and cholesterol metabolism. Klin Wochenschr. 1983 Mar 1;61(5):225–232. [PubMed] [Google Scholar]
• Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. Am J Hum Genet. 1980 May;32(3):339–347. [PMC free article] [PubMed] [Google Scholar]
• Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry. 1981 Feb 17;20(4):1033–1041. [PubMed] [Google Scholar]
• Rall SC, Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982 Apr 25;257(8):4171–4178. [PubMed] [Google Scholar]
• Rall SC, Jr, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4696–4700. [PMC free article] [PubMed] [Google Scholar]
• Weisgraber KH, Rall SC, Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981 Sep 10;256(17):9077–9083. [PubMed] [Google Scholar]
• Mahley RW, Innerarity TL. Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta. 1983 May 24;737(2):197–222. [PubMed] [Google Scholar]
• Brown MS, Goldstein JL. Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J Clin Invest. 1983 Sep;72(3):743–747. [PMC free article] [PubMed] [Google Scholar]
• Hui DY, Innerarity TL, Mahley RW. Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E. J Biol Chem. 1984 Jan 25;259(2):860–869. [PubMed] [Google Scholar]
• Mahley RW, Hui DY, Innerarity TL, Weisgraber KH. Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B,E and apo-E receptors. J Clin Invest. 1981 Nov;68(5):1197–1206. [PMC free article] [PubMed] [Google Scholar]
• Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, et al. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest. 1981 Oct;68(4):1075–1085. [PMC free article] [PubMed] [Google Scholar]
• Innerarity TL, Friedlander EJ, Rall SC, Jr, Weisgraber KH, Mahley RW. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. J Biol Chem. 1983 Oct 25;258(20):12341–12347. [PubMed] [Google Scholar]
• Weisgraber KH, Innerarity TL, Harder KJ, Mahley RW, Milne RW, Marcel YL, Sparrow JT. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem. 1983 Oct 25;258(20):12348–12354. [PubMed] [Google Scholar]
• Utermann G, Pruin N, Steinmetz A. Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. Clin Genet. 1979 Jan;15(1):63–72. [PubMed] [Google Scholar]
• Rall SC, Jr, Weisgraber KH, Innerarity TL, Mahley RW. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. J Clin Invest. 1983 Apr;71(4):1023–1031. [PMC free article] [PubMed] [Google Scholar]
• Chait A, Hazzard WR, Albers JJ, Kushwaha RP, Brunzell JD. Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia. Metabolism. 1978 Sep;27(9):1055–1066. [PubMed] [Google Scholar]
• Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972 Feb 21;260(2):212–221. [PubMed] [Google Scholar]
• LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
• BARTLETT GR. Phosphorus assay in column chromatography. J Biol Chem. 1959 Mar;234(3):466–468. [PubMed] [Google Scholar]
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. [PubMed] [Google Scholar]
• Kinnunen PK. Purification of bovine milk lipoprotein lipase with the aid of detergent. Med Biol. 1977 Jun;55(3):187–191. [PubMed] [Google Scholar]
• Kuusi T, Kinnunen PK, Ehnholm C, Nikkilä EA. A simple purification procedure for rat hepatic lipase. FEBS Lett. 1979 Feb 15;98(2):314–318. [PubMed] [Google Scholar]
• Huttunen JK, Ehnholm C, Kinnunen PK, Nikkilä EA. An immunochemical method for the selective measurement of two triglyceride lipases in human postheparin plasma. Clin Chim Acta. 1975 Sep 16;63(3):335–347. [PubMed] [Google Scholar]
• Havel RJ, Kane JP. Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins. Proc Natl Acad Sci U S A. 1973 Jul;70(7):2015–2019. [PMC free article] [PubMed] [Google Scholar]
• Deckelbaum RJ, Eisenberg S, Fainaru M, Barenholz Y, Olivecrona T. In vitro production of human plasma low density lipoprotein-like particles. A model for very low density lipoprotein catabolism. J Biol Chem. 1979 Jul 10;254(13):6079–6087. [PubMed] [Google Scholar]
• Deckelbaum RJ, Eisenberg S, Oschry Y, Butbul E, Sharon I, Olivecrona T. Reversible modification of human plasma low density lipoproteins toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters. J Biol Chem. 1982 Jun 10;257(11):6509–6517. [PubMed] [Google Scholar]
• Malloy MJ, Kane JP. Hypolipidemia. Med Clin North Am. 1982 Mar;66(2):469–484. [PubMed] [Google Scholar]
• Chung BH, Segrest JP. Resistance of a very low density lipoprotein subpopulation from familial dysbetalipoproteinemia to in vitro lipolytic conversion to the low density lipoprotein density fraction. J Lipid Res. 1983 Sep;24(9):1148–1159. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences